Brief: Cartesian Therapeutics Highlights Progress And 2025 Strategic Priorities
13/01/2025 13:39
Jan 13 (Reuters) - Cartesian Therapeutics Inc RNAC.O :
* CARTESIAN THERAPEUTICS HIGHLIGHTS PROGRESS AND 2025
STRATEGIC
PRIORITIES ACROSS PIPELINE OF MRNA CELL THERAPIES FOR AUTOIMMUNE
DISEASES
* CASH RESOURCES EXPECTED TO SUPPORT OPERATIONS INTO
MID-2027
* PHASE 3 AURORA TRIAL OF DESCARTES-08 TO COMMENCE IN 1H25
* PHASE 2 SLE TRIAL OF DESCARTES-08 ONGOING, DATA READOUT
EXPECTED
2H25
Source text: ID:nGNX4wKr8H
Further company coverage: RNAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview